193 related articles for article (PubMed ID: 21945487)
1. On the leveling-off properties of the new bioequivalence limits for highly variable drugs of the EMA guideline.
Karalis V; Symillides M; Macheras P
Eur J Pharm Sci; 2011 Nov; 44(4):497-505. PubMed ID: 21945487
[TBL] [Abstract][Full Text] [Related]
2. Geometric mean ratio-dependent scaled bioequivalence limits with leveling-off properties.
Karalis V; Macheras P; Symillides M
Eur J Pharm Sci; 2005 Sep; 26(1):54-61. PubMed ID: 15955680
[TBL] [Abstract][Full Text] [Related]
3. Comparison of the reference scaled bioequivalence semi-replicate method with other approaches: focus on human exposure to drugs.
Karalis V; Symillides M; Macheras P
Eur J Pharm Sci; 2009 Aug; 38(1):55-63. PubMed ID: 19524039
[TBL] [Abstract][Full Text] [Related]
4. Bioequivalence of highly variable drugs: a comparison of the newly proposed regulatory approaches by FDA and EMA.
Karalis V; Symillides M; Macheras P
Pharm Res; 2012 Apr; 29(4):1066-77. PubMed ID: 22203326
[TBL] [Abstract][Full Text] [Related]
5. Quantitative assessment of the switchability of generic products.
Karalis V; Bialer M; Macheras P
Eur J Pharm Sci; 2013 Nov; 50(3-4):476-83. PubMed ID: 23981332
[TBL] [Abstract][Full Text] [Related]
6. Novel scaled bioequivalence limits with leveling-off properties.
Kytariolos J; Karalis V; Macheras P; Symillides M
Pharm Res; 2006 Nov; 23(11):2657-64. PubMed ID: 17048119
[TBL] [Abstract][Full Text] [Related]
7. Variability and impact on design of bioequivalence studies.
Van Peer A
Basic Clin Pharmacol Toxicol; 2010 Mar; 106(3):146-53. PubMed ID: 20041877
[TBL] [Abstract][Full Text] [Related]
8. The role of the upper sample size limit in two-stage bioequivalence designs.
Karalis V
Int J Pharm; 2013 Nov; 456(1):87-94. PubMed ID: 23954235
[TBL] [Abstract][Full Text] [Related]
9. Novel scaled average bioequivalence limits based on GMR and variability considerations.
Karalis V; Symillides M; Macheras P
Pharm Res; 2004 Oct; 21(10):1933-42. PubMed ID: 15553242
[TBL] [Abstract][Full Text] [Related]
10. The bioequivalence of highly variable drugs and drug products.
Midha KK; Rawson MJ; Hubbard JW
Int J Clin Pharmacol Ther; 2005 Oct; 43(10):485-98. PubMed ID: 16240706
[TBL] [Abstract][Full Text] [Related]
11. Scaling or wider bioequivalence limits for highly variable drugs and for the special case of C(max).
Tothfalusi L; Endrenyi L; Midha KK
Int J Clin Pharmacol Ther; 2003 May; 41(5):217-25. PubMed ID: 12776813
[TBL] [Abstract][Full Text] [Related]
12. Sample sizes for designing bioequivalence studies for highly variable drugs.
Tothfalusi L; Endrenyi L
J Pharm Pharm Sci; 2012; 15(1):73-84. PubMed ID: 22365089
[TBL] [Abstract][Full Text] [Related]
13. Model-based analyses of bioequivalence crossover trials using the stochastic approximation expectation maximisation algorithm.
Dubois A; Lavielle M; Gsteiger S; Pigeolet E; Mentré F
Stat Med; 2011 Sep; 30(21):2582-600. PubMed ID: 21793036
[TBL] [Abstract][Full Text] [Related]
14. Regulatory and study conditions for the determination of bioequivalence of highly variable drugs.
Endrenyi L; Tothfalusi L
J Pharm Pharm Sci; 2009; 12(1):138-49. PubMed ID: 19470298
[TBL] [Abstract][Full Text] [Related]
15. A modified large sample approach in the assessment of population bioequivalence.
Quiroz J; Ting N; Wei GC; Burdick RK
J Biopharm Stat; 2000 Nov; 10(4):527-44. PubMed ID: 11104391
[TBL] [Abstract][Full Text] [Related]
16. An alternative single dose parameter to avoid the need for steady-state studies on oral extended-release drug products.
Paixão P; Gouveia LF; Morais JA
Eur J Pharm Biopharm; 2012 Feb; 80(2):410-7. PubMed ID: 22108491
[TBL] [Abstract][Full Text] [Related]
17. Critical considerations into the new EMA guideline on bioequivalence.
Marzo A; Fontana E
Arzneimittelforschung; 2011; 61(4):207-20. PubMed ID: 21650079
[TBL] [Abstract][Full Text] [Related]
18. The new European Medicines Agency guideline on the investigation of bioequivalence.
Morais JA; Lobato Mdo R
Basic Clin Pharmacol Toxicol; 2010 Mar; 106(3):221-5. PubMed ID: 20070293
[TBL] [Abstract][Full Text] [Related]
19. An area correction method to reduce intrasubject variability in bioequivalence studies.
Abdallah HY
J Pharm Pharm Sci; 1998; 1(2):60-5. PubMed ID: 10945919
[TBL] [Abstract][Full Text] [Related]
20. Computer simulations of bioequivalence trials: selection of design and analyte in BCS drugs with first-pass hepatic metabolism: linear kinetics (I).
Fernández-Teruel C; Nalda Molina R; González-Alvarez I; Navarro-Fontestad C; García-Arieta A; Casabó VG; Bermejo M
Eur J Pharm Sci; 2009 Jan; 36(1):137-46. PubMed ID: 19028574
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
